Four Days in Lille: Noventure at ESPGHAN 2026
Last week, Noventure took part in the 58th Annual Meeting of ESPGHAN in Lille, France, where our team presented the Tasectan® paediatric range to clinicians from across Europe and beyond.
Tasectan and Xilaplus in the new German GPGN Guidelines
Z Gastroenterol 2024; 62(09): 1574-1643 Getting into treatment guidelines is lengthy, especially for new products that need time to gather sufficient scientific and real-life evidence. For this reason, we are glad to announce that Noventure´s mucoprotectants gelatin tannate and xyloglucan have been mentioned on good terms in the new guideline [...]
Partner Devicare, S.L.
We would like to announce our new partnership with Devicare, S.L., to bring Utipro Plus AF into the Spanish market! We’re excited about this new alliance and grateful for the trust placed in us. Interested in exploring business opportunities with us? Contact us! https://noventure.com/contact-us [...]
Tasectan MDR Approved
GREAT NEWS! Noventure is delighted to announce that our medical device Tasectan has just been granted a new CЄ Certificate under MDR Regulation. With 3,7 Mio packs, equivalent to more than 51 Mio of standard units sold through our licensees in 34 countries during 2023, the Tasectan franchise is already [...]
UTIPRO® PLUS AF reaches Central Asia
We are happy to inform that Utipro® Plus AF is ready to land in Central Asia thanks to its very recent registration in Kazakhstan. All evidence supporting the product has been evaluated by the Kazakh Ministry of Health who validated the CE certification of the product and accepted its medical [...]
Do you know Noventure?
You may know that Noventure is a Spanish company from Barcelona, part of Ferrer, specialized in medical devices & innovative food supplements. But… who are we in the team, what do we actually do and most importantly… how do we do it❓ Follow us on LinkedIn to find out all the [...]
Press Release: Noventure acquires Ulkox® and Oleoabrax®, two medical devices based on patented new wound-healing technology
Acquisition allows Noventure to maintain focus on medical devices and grow therapeutic areas in which it operates Medical devices contain Olea Europaea leaf extract, showing healing properties for ulcers and skin wounds Innovative products are CE marked and available for licensing worldwide Barcelona, Spain, April 19, 2021 – Noventure, specialized in licensing [...]
First launch of UTIPRO® PLUS AF in EUROPE
We are pleased to announce the launch of UTIPRO® PLUS AF in Portugal. Portugal is the first European country in which UTIPRO® PLUS AF has been launched in its composition free from ingredients of animal origin. The product is distributed by Sangool, a Portuguese company specialized in the detailing and the [...]
Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys
Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies in adults, children, and infants. XILAPLUS® is a class III medical device and complies with the [...]
UTIPRO® PLUS AF strengthens its presence in EUROPE
We are pleased to announce the launch of UTIPRO® PLUS AF in the Republic of Ireland. UTIPRO® PLUS AF, in its composition free from ingredients of animal origin, has been recently launched in the Republic of Ireland, thus further enlarging its presence across Europe. The product is distributed by Pamex, [...]